Skip to main content
NASDAQ:SPRB

Spruce Biosciences News Headlines

$15.25
+0.65 (+4.45 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.00
$15.48
50-Day Range
$14.60
$17.46
52-Week Range
$14.18
$35.60
Volume62,482 shs
Average Volume56,355 shs
Market Capitalization$355.36 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Spruce Biosciences (NASDAQ SPRB) News Headlines Today

SourceHeadline
Spruce Biosciences to Participate in the RBC Capital Markets Global Healthcare ConferenceSpruce Biosciences to Participate in the RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - May 14 at 5:09 AM
Spruce Biosciences (NASDAQ:SPRB) Announces Quarterly  Earnings ResultsSpruce Biosciences (NASDAQ:SPRB) Announces Quarterly Earnings Results
americanbankingnews.com - May 13 at 11:56 AM
Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate UpdatesSpruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates
finance.yahoo.com - May 12 at 5:01 PM
Spruce Biosciences, Inc. (NASDAQ:SPRB) Director Camilla V. Simpson Sells 14,045 SharesSpruce Biosciences, Inc. (NASDAQ:SPRB) Director Camilla V. Simpson Sells 14,045 Shares
americanbankingnews.com - May 5 at 4:34 AM
Spruce Biosciences, Inc. Rings The Closing BellSpruce Biosciences, Inc. Rings The Closing Bell
nasdaq.com - March 29 at 8:24 PM
Spruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate UpdatesSpruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate Updates
finance.yahoo.com - March 22 at 8:41 PM
Spruce Biosciences Presents Phase 1 and 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia from Endocrine Society’s 2021 Annual MeetingSpruce Biosciences Presents Phase 1 and 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia from Endocrine Society’s 2021 Annual Meeting
finance.yahoo.com - March 17 at 1:04 PM
Spruce Biosciences to Announce Phase 1 and 2 Data of Tildacerfont at Endocrine Society’s 2021 Annual MeetingSpruce Biosciences to Announce Phase 1 and 2 Data of Tildacerfont at Endocrine Society’s 2021 Annual Meeting
finance.yahoo.com - March 2 at 11:44 AM
Spruce Biosciences to Participate in Upcoming Investor ConferencesSpruce Biosciences to Participate in Upcoming Investor Conferences
finance.yahoo.com - February 17 at 7:21 PM
What Type Of Shareholders Make Up Spruce Biosciences, Inc.s (NASDAQ:SPRB) Share Registry?What Type Of Shareholders Make Up Spruce Biosciences, Inc.'s (NASDAQ:SPRB) Share Registry?
finance.yahoo.com - January 12 at 12:09 PM
Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021
finance.yahoo.com - January 6 at 8:10 AM
Spruce Biosciences Added to Russell 2000®, 3000® and Microcap® IndexesSpruce Biosciences Added to Russell 2000®, 3000® and Microcap® Indexes
finance.yahoo.com - December 17 at 6:24 PM
Spruce Biosciences Inc.Spruce Biosciences Inc.
barrons.com - November 20 at 6:03 PM
Spruce Biosciences, Inc. (SPRB)Spruce Biosciences, Inc. (SPRB)
realmoney.thestreet.com - November 5 at 10:34 PM
Spruce Biosciences to Participate in the Credit Suisse 29th Annual Virtual Healthcare ConferenceSpruce Biosciences to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference
finance.yahoo.com - November 4 at 8:15 PM
Spruce Biosciences Prices IPO Of 6.0 Mln Shares At $15, The Mid Of Expected RangeSpruce Biosciences Prices IPO Of 6.0 Mln Shares At $15, The Mid Of Expected Range
markets.businessinsider.com - October 31 at 11:25 PM
Novo Holdings reports 21.5% stake in Spruce BiosciencesNovo Holdings reports 21.5% stake in Spruce Biosciences
seekingalpha.com - October 19 at 7:23 AM
Spruce Biosciences reports 21.5% stake in Spruce BiosciencesSpruce Biosciences reports 21.5% stake in Spruce Biosciences
seekingalpha.com - October 19 at 7:23 AM
This page was last updated on 5/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.